abciximab |
GPIIbIIIa/ |
Réopro |
Centocor / Janssen / |
|
CD11b/CD18 |
|
Eli Lilly and Company |
|
αvβ3 |
|
|
adalimumab |
TNF-α |
Humira |
Cambridge Antibody Technology(CAT) / AbbVie |
adécatumumab |
EpCAM |
- |
Micromet / Merck |
aducanumab |
amyloïde β |
- |
Neurimmune / Biogen |
|
(A-β fibrillaire) |
|
|
ado-trastuzumab emtansine (DM1) |
HER2/neu |
Kadcyla |
Genentech (Roche) / Lonza |
aérubumab |
Ps°°°° |
Aerucin |
Aridis Pharmaceuticals |
alemtuzumab |
CD52 |
Lemtrada |
Sanofi Genzyme |
alirocumab |
PCSK9++
|
Praluent |
Sanofi-Aventis |
anifrolumab |
IFNAR1 |
- |
Medimmune LLC / AstraZeneca |
atézolizumab |
PD-L1 |
Tecentriq |
Genentech (Roche+) |
avélumab |
PD-L1 |
Bavencio |
Merck Sharp & Dohme / Pfizer |
basiliximab |
IL-2Rα (CD25) |
Simulect |
Novartis |
bavituximab |
Phosphatidylsérine |
- |
Peregrine Pharmaceuticals |
bélantamab mafodotine. |
BCMA (TNFRSF17) |
- |
GlaxoSmithKline |
bélimumab |
BLyS (BAFF) |
Benlysta |
GlaxoSmithKline |
benralizumab |
IL-5R |
Fasenra |
AstraZeneca |
bévacizumab |
VEGF-A |
Avastin |
Roche |
bézlotoxumab |
entérotoxine B |
Zinplava |
Merck Sharp & Dohme |
|
Clostridium difficile
|
|
|
bimékizumab |
IL-17A/F |
- |
UCB |
blésélumab |
CD40 |
- |
Kiowa Kirin Pharmaceuticals |
blinatumomab |
CD3εxCD19 |
Blincyto |
Micromet / Amgen |
bococizumab |
PCSK9 |
- |
Pfizer |
brentuximab védotine |
CD30 |
Adcetris |
Seattle Genetics |
burosumab |
FGF23 |
Crysvita |
Kyowa Hakko Kirin Pharma |
cabiralizumab |
CSF1-R (CD115) |
- |
Five Prime Therapeutics/ Bristol-Myers Squibb |
camrélizumab |
PD-1 |
- |
Jiangsu HengRui Medicine |
canakinumab |
IL-1β |
Ilaris |
Novartis |
caplacizumab |
vWF |
Cablivi |
Sanofi |
catumaxomab |
CD3ε x EpCAM |
Removab |
Fresenius Biotech / Trion Pharma |
cémiplimab |
PD-1 (CD279) |
Libtayo |
Regeneron / Sanofi |
cergutuzumab amunaleukin |
ACE |
- |
Roche |
certolizumab pégol |
TNF-α |
Cimzia |
UCB Pharma |
cétrélimab |
PD-1 (CD279) |
- |
Janssen |
cétuximab |
EGF-R |
Erbitux |
Imclone / Merck Serono |
conatumumab |
TRAIL-R2(DR5, APO-2) |
- |
Amgen / Takeda |
concizumab |
TFPI°°° |
- |
Novo Nordisk |
cosfroviximab |
Gp surface Ebola virus≠
|
ZMapp |
Mapp Biopharmaceuticals |
crénézumab |
amyloïde β(A-β fibrillaire) |
- |
Genentech (Roche) |
cusatuzumab |
CD70 |
- |
Argenx / Janssen Cilag |
dacétuzumab |
CD40 |
- |
Seattle Genetics / Genentech |
daclizumab |
CD25 (IL-2Rα) |
Zinbryta |
Protein Design Labs BioPharma / Biogen / AbbVie |
dapirolizumab pégol |
CD40L (CD154) |
- |
UCB Pharma |
daratumumab |
CD38 |
Darzalex |
Janssen |
dénosumab |
RANKL |
Prolia / Xgeva |
Amgen |
dépatuxizumab madofotine |
EGF-RvIII |
- |
AbbVie |
dinutuximab bêta |
GD2 |
Qarziba |
EUSA Pharma / Jazz Pharmaceuticals |
diridavumab |
HA##
|
- |
Janssen |
drozitumab |
TRAIL-R2(DR5, APO-2) |
- |
Genentech (Roche) |
dupilumab |
IL-4/IL-13Rα |
Dupixent |
Regeneron / Sanofi |
durvalumab |
PD-L1 |
Imfinzi |
MedImmune LLC / AstraZeneca |
éculizumab |
C5 |
Soliris |
Alexion Pharmaceuticals |
éfalizumab |
CD11a |
Raptiva |
Genentech / Merck Serono |
éfungumab |
Hsp90≠≠
|
Mycograb |
NeuTec Pharma / Novartis |
élotuzumab |
SLAMF7 |
Empliciti |
Bristol-Myers Squibb |
émactuzumab |
CSF1-R (CD115) |
- |
Genentech / Roche |
émicizumab |
facteurs IXa x X |
Hemlibra |
Chugai (Roche) |
enfortumab védotin |
nectine 4 |
- |
Seattle Genetics |
énoblituzumab. |
B7-H3 (CD276) |
- |
MacroGenics |
eptinézumab |
CGRP$$
|
- |
Alder Biopharmaceuticals |
érénumab |
CGRP |
Aimovig |
Amgen / Novartis |
erlizumab |
CD18 |
- |
Genentech (Roche) |
ertumaxomab |
HER2/neu x CD3εx RFcγI/II/III |
- |
Fresenius Biotech |
étanercept |
TNF-α |
Enbrel |
Pfizer |
étigilimab |
TIGIT |
- |
Oncomed / Mereo BioPharma |
énoblituzumab |
B7-H3 (CD276) |
- |
MacroGenics |
évolocumab |
PCSK9++
|
Repatha |
Amgen |
farlétuzumab |
Folate receptor 1 |
- |
Morphotek |
felvizumab |
F§§(protéine de fusion) |
- |
GlaxoSmithKline |
flotétuzumab |
CD123 x CD3e |
- |
MacroGenics |
foravirumab |
gp I et gpIII§§§
|
- |
Crucell / Sanofi Pasteur |
frémanézumab |
CGRP |
Ajovy |
Teva |
frésolimumab |
TGF-β |
- |
Genzyme (Sanofi) |
futuximab |
EGFR (Erb1, HER1) |
- |
Symphogen |
galcanézumab |
CGRP |
Emgality |
Eli Lilly & Company |
galiximab |
CD80 |
Biogen (ex-Biogen Idec) |
|
ganténérumab |
amyloïde β(A-β fibrillaire) |
- |
Roche |
gédivumab |
HA |
- |
Genentech (Roche) |
gemtuzumab ozogamicin |
CD33 |
Mylotarg |
Celltech / Wyeth |
golimumab |
TNF-α |
Simponi |
Janssen |
grémubamab |
PcrV et PsI++++
|
- |
MedImmune (AstraZeneca) |
guselkumab |
IL-23Rp19 |
Tremfya |
Janssen |
ibalizumab |
CD4 |
Trogarzo |
Theratechnologies |
ibritumomab tiuxetan |
CD20 |
Zevalin |
Spectrum Pharmaceuticals / Acrotech Biopharma |
idarucizumab |
Dabigatran |
Praxbind |
Boehringer Ingelheim |
inclacumab |
Sélectine P |
- |
Roche |
infliximab |
TNF-α |
Remicade |
NYU°° / Janssen |
inotuzumab ozogamicine |
CD22 |
Besponsa |
Pfizer |
ipilimumab. |
CTLA-4 |
Yervoy |
Medarex / Bristol-Myers Squibb |
isatuximab |
CD38 |
- |
Sanofi |
iscalimab |
CD40 |
- |
Xoma / Novartis |
ixékizumab |
IL-17A |
Taltz |
Eli Lilly & Company |
lacnotuzumab |
CSF-R (CD115) |
- |
Novartis |
lanadélumab |
kallicréine |
Takhzyro |
Takeda / Shire |
larcaviximab |
Gp surface Ebola virus |
ZMapp |
Mapp Biopharmaceuticals |
lenvervimab |
Ag HBs§
|
- |
GC Pharma |
léronlimab |
CCR5 |
- |
CytoDyn |
lexatumumab |
TRAIL-R2(DR5, APO-2) |
- |
Human Genome Sciences / Cambridge Antibody
Technology |
ligélizumab |
IgE |
- |
Novartis |
lirilumab |
KIR2DL1/L2/L3-
|
- |
Innate Pharma / Bristol-Myers Squibb |
loncastuximab tésirine |
CD19 |
- |
ADC Therapeutics |
lucatumumab |
CD40 |
- |
Chiron / Xoma / Novartis |
lulizumab pégol |
CD28 |
- |
Bristol-Myers Squibb |
lumiliximab |
CD23 (RFcεII) |
- |
Biogen Idec |
mapatumumab |
TRAIL-R1 (DR4) |
- |
Human Genome Sciences (GlaxoSmith Kline)/ Cambridge
Antibody Technology (AstraZeneca) |
magrolimab |
CD47 |
- |
Forty Seven Inc. |
mirvétuximab soravtansine |
FOLR1 |
- |
ImmunoGen |
mitazalimab |
CD40 |
- |
Alligator Biosciences / Janssen |
modotuximab |
HER1 (ErbB-1) |
- |
Symphogen |
mogamulizumab |
CCR4 |
Poteligeo |
BioWa / Kyowa Hakko Kirin Pharma |
monalizumab |
CD94/NKG2A |
- |
Innate Pharma / AstraZeneca |
mosunétuzumab |
CD20 x CD3e |
- |
Genentech (Roche) |
motavizumab |
F(protéine de fusion) |
Numax |
MedImmune (AstraZeneca) |
moxétumomab pasudotox |
CD22 |
Lumoxiti |
AstraZeneca / Innate Pharma |
muromonab |
CD3ε |
Orthoclone OKT3 |
Janssen-Cilag |
naptumomab estéfénatox |
5T4°°°°° |
- |
Active Biotech |
natalizumab |
α4β1(VLA-4$) |
Tysabri |
Biogen / Élan |
nécitumumab |
EGFR |
Portrazza |
Eli Lilly & Company |
niversimab |
F(protéine de fusion) |
- |
MedImmune (AstraZeneca)Sanofi Pasteur |
nivolumab |
PD-1 |
Opdivo |
Medarex / Bristol-Myers Squibb |
obiltoxaximab |
PA# exotoxine(Anthrax) |
Anthim |
Elusys Therapeutics |
obinutuzumab |
CD20 |
Gazyvaro / Gazyva |
Glycart Biotechnology (Roche) |
ocrélizumab |
CD20 |
Ocrevus |
Roche |
ofatumumab |
CD20 |
Arzerra |
Genmab / GlaxoSmithKline |
omalizumab |
IgE |
Xolair |
Novartis |
oportuzumab monatox |
EpCAM |
Vicinium |
Viventia Bio |
otélixizumab |
CD3 |
- |
Tolerx / GlaxoSmithKline |
otilimab |
GM-CSF |
- |
Morphosys / GlaxoSmithKline |
oxélumab |
Ox40L (CD223) |
- |
Genentech (Roche) |
pagibaximab |
Acide lipotéichoïque$$$
|
- |
Biosynexus |
palivizumab |
VRS+++
|
Synagis |
MedImmune (AstraZeneca) |
panitumumab |
EGFR |
|
|
patéclizumab |
Lymphotoxine-α |
- |
Genentech (Roche) |
pembrolizumab |
PD-1 |
Keytruda |
Merck Sharp and Dohme |
pertuzumab |
HER2/neu |
Perjeta |
Genentech (Roche) |
pexélizumab |
C5 |
- |
Alexion Pharmaceuticals |
pidilizumab |
PD-1 (CD279) |
- |
Medivation |
polatuzumab védotine-piqq |
CD79b |
Polivy |
Genentech (Roche) |
porgaviximab |
Gp de surface |
ZMapp |
Mapp Biopharmaceutical / Public Health Agency of
Canada |
prézalizumab |
ICOS-L (CD275) |
- |
Amgen |
ramucirumab |
VEGF-R2 (KDR) |
Cyramza |
Eli Lilly & Company |
ranibizumab |
VEGF-A |
Lucentis |
Genentech (Roche) / Novartis |
ravagalimab |
CD40 |
- |
AbbVie |
ravulizumab |
C5 |
Ultomiris |
Alexion Pharmaceuticals |
raxibacumab |
PA exotoxine(Anthrax) |
ABthrax |
Human Genome Sciences / GlaxoSmithKline |
rélatlimab |
LAG-3 (CD223) |
- |
Bristol-Myers Squibb |
risankizumab |
IL-23Rp19 |
- |
Boehringer Ingelheim / AbbVie |
rituximab |
CD20 |
Rituxan/Mabthera |
Genentech (Roche) |
rolédumab |
Rhésus D |
- |
LFB° Group |
rontalizumab |
IFN-α |
- |
Genentech / Chugai Pharmaceuticals |
rovalpituzumab tésirine |
DLL3###
|
Rova-T |
Stemcentrx / Abbvie |
rovélizumab |
CD18 |
- |
Icos Corp. (Eli Lilly & Company) |
ruplizumab |
CD40L (CD154) |
Antova |
Biogen |
sacituzumab govitécan |
Trop-2 |
- |
Immunomedics |
sarilumab |
IL-6Rα (CD126) |
Kevzara |
Regeneron / Sanofi Aventis |
sécukinumab |
IL-17A |
Cosentyx |
Novartis |
sélicrélumab |
CD40 |
- |
Roche |
sévirumab |
gH###
|
- |
PDL BioPharma / Novartis |
sibrotuzumab |
Fibroblastactivation protein (FAP) |
- |
Boehringer Ingelheim Pharma |
sintilimab |
PD-1 (CD279) |
Tyvit |
Innovent Biologics / Eli Lilly and Co |
spartalizumab |
PD-1 (CD279) |
- |
Novartis |
suptavumab |
F(protéine de fusion) |
- |
Regeneron Pharmaceuticals |
suvratoxumab |
Staphylococcus aureus alpha toxin |
- |
MedImmune (AstraZeneca) |
tavolimab |
OX-40 (CD134) |
- |
MedImmune (AstraZeneca) |
téfibazumab |
ClfA####
|
Aurexis |
Inhibitex (Bristol-Myers Squibb) |
ténéliximab |
CD40 |
- |
? |
téplizumab |
CD3 |
- |
ProventionBio |
théralizumab |
CD28 |
- |
TeGenero Immuno Therapeutics / TheraMAB |
tigatuzumab |
TRAIL-R2(DR5, APO-2) |
- |
Daiichi Sankyo |
tiragolumab |
TIGIT |
- |
Genentech (Roche) |
tislélizumab |
PD-1 (CD279) |
- |
Beigene / Celgene (Bristol-Myers Squibb) |
tocilizumab |
IL-6Rα (CD126) |
Actemra/RoActemra |
Chugai (Roche) |
toralizumab |
CD40L (CD154) |
- |
Idec Pharmaceuticals |
toripalimab |
PD-1 (CD279) |
- |
Shanghai Junshi Bioscience Co |
tositumomab |
CD20 |
Bexxar |
GlaxoSmithKline |
trastuzumab |
HER2/neu |
Herceptine |
Genentech / Roche |
trastuzumab déruxtécan |
HER2/neu |
- |
Daiichi Sankyo |
trastuzumab duocarmazine |
HER2/neu |
- |
Synthon Biopharmaceuticals BV |
trémélimumab |
CTLA-4 (CD152) |
- |
Pfizer / Medimmune LLCAstraZeneca |
ublituximab |
CD20 |
- |
LFB° Group / TG Therapeutics |
urélumab |
4-1BB (CD137) |
- |
Bristol-Myers Squibb |
ustékinumab |
IL-23Rp40 |
Stelara |
Janssen |
utomilumab |
4-1BB (CD137) |
- |
Pfizer |
vanalimab |
CD40 |
- |
Alligator BioScience /Janssen Biotech |
varlilumab |
CD27 |
- |
Celldex therapeutics |
védolizumab |
α4β7 |
Entyvio |
Takeda |
veltuzumab |
CD20 |
- |
Immunomedics |
volociximab |
α5β1 |
- |
PDL BioPharma / Biogen Idec |
vopratélimab |
ICOS (CD278) |
- |
Jounce Therapeutics |